The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Genomma Lab InternacionalB de CV's share price is MXN15.04.
Genomma Lab InternacionalB de CV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN17.74. Hence, Genomma Lab InternacionalB de CV's PS Ratio for today is 0.85.
Good Sign:
Genomma Lab Internacional SAB de CV stock PS Ratio (=0.84) is close to 10-year low of 0.76.
During the past 13 years, Genomma Lab InternacionalB de CV's highest 3-Year average Revenue per Share Growth Rate was 56.30% per year. The lowest was 1.90% per year. And the median was 9.00% per year.
Back to Basics: PS Ratio
Genomma Lab InternacionalB de CV (MEX:LABB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Genomma Lab InternacionalB de CV PS Ratio Related Terms
Genomma Lab InternacionalB de CV PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's PS Ratio distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's PS Ratio falls into.
Genomma Lab InternacionalB de CV PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Genomma Lab InternacionalB de CV's Share Price of today is MXN15.04. Genomma Lab InternacionalB de CV's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN17.74.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Genomma Lab InternacionalB de CV (MEX:LABB) has a PS Ratio of 0.85 as of Jun. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 38% below median its historical median of 1.37. Over the past decade, Genomma Lab InternacionalB de CV's PS Ratio has ranged from 0.76 to 2.28. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #204 out of 953 companies in the Drug Manufacturers industry, placing it in the top 21.4%.
Is Genomma Lab InternacionalB de CV's PS Ratio too high?
Genomma Lab InternacionalB de CV's current PS Ratio of 0.85 is 38% below median its 10-year median of 1.37. Over the past 10 years, this metric has ranged from a low of 0.76 to a high of 2.28. The Drug Manufacturers industry median PS Ratio is 2.20. Genomma Lab InternacionalB de CV's value of 0.85 is 61.4% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #204 out of 953 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #204 out of 953 companies for PS Ratio. This places Genomma Lab InternacionalB de CV in the top 21% of its industry — outperforming the majority of peers. The industry median PS Ratio is 2.20. Genomma Lab InternacionalB de CV's value of 0.85 is 61.4% below this benchmark. Historically, Genomma Lab InternacionalB de CV's own PS Ratio has ranged from 0.76 to 2.28 over the past decade. While the company's 10-year median is 1.37 vs. the industry median of 2.20, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.20, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current PS Ratio of 0.85 is 61.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current PS Ratio is 0.85, which is 38% below median its own 10-year median of 1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current PS Ratio is 0.85, which is 38% below median its 10-year median of 1.37 and 61.4% below the Drug Manufacturers industry median of 2.20. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current PS Ratio is 0.85 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
PS Ratio: 0.85 (38% below median its 10-year median of 1.37)
GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
Industry Position: 61.4% below the Drug Manufacturers median (#204 of 953)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
